160 related articles for article (PubMed ID: 38478154)
21. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
[TBL] [Abstract][Full Text] [Related]
22. Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Ueda Y; Matsubara N; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Clin Genitourin Cancer; 2017 Apr; 15(2):320-325. PubMed ID: 27601278
[TBL] [Abstract][Full Text] [Related]
23. Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer.
Perez-Lopez R; Lorente D; Blackledge MD; Collins DJ; Mateo J; Bianchini D; Omlin A; Zivi A; Leach MO; de Bono JS; Koh DM; Tunariu N
Radiology; 2016 Jul; 280(1):151-60. PubMed ID: 26807894
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of the bone scan index in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
Song H; Jin S; Xiang P; Hu S; Jin J
BMC Cancer; 2020 Mar; 20(1):238. PubMed ID: 32197590
[TBL] [Abstract][Full Text] [Related]
25. Predicting the Prognosis of Prostate Cancer Bone Metastasis Using the Bone Scan Index and Hot Spots Calculated Using VSBONEⓇ Bone Scan Index from Tc-99m-Hydroxymethylene Diphosphonate Bone Scintigraphy.
Higashiyama S; Yoshida A; Kawabe J
Urol Int; 2022; 106(9):963-969. PubMed ID: 35249033
[TBL] [Abstract][Full Text] [Related]
26. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
Sonpavde G; Pond GR; Templeton AJ; Fandi A; Tombal B; Rosenthal M; Armstrong AJ; Petrylak DP
Eur Urol; 2016 Jun; 69(6):980-3. PubMed ID: 26497922
[TBL] [Abstract][Full Text] [Related]
27. Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study.
Nakajima K; Mizokami A; Matsuyama H; Ichikawa T; Kaneko G; Takahashi S; Shiina H; Horikoshi H; Hashine K; Sugiyama Y; Miyao T; Kamiyama M; Harada K; Ito A;
Int J Urol; 2021 Sep; 28(9):955-963. PubMed ID: 34148264
[TBL] [Abstract][Full Text] [Related]
28. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Armstrong AJ; Anand A; Edenbrandt L; Bondesson E; Bjartell A; Widmark A; Sternberg CN; Pili R; Tuvesson H; Nordle Ö; Carducci MA; Morris MJ
JAMA Oncol; 2018 Jul; 4(7):944-951. PubMed ID: 29799999
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of two-dimensional total bone uptake (2D-TBU) and bone scan index (BSI) extracted from active bone metastatic burden on the bone scintigraphy in patients with radium-223 treatment.
Fukai S; Daisaki H; Umeda T; Shimada N; Terauchi T; Koizumi M
Ann Nucl Med; 2024 Jun; 38(6):450-459. PubMed ID: 38517659
[TBL] [Abstract][Full Text] [Related]
30. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
[TBL] [Abstract][Full Text] [Related]
31. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES
Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.
Sabbatini P; Larson SM; Kremer A; Zhang ZF; Sun M; Yeung H; Imbriaco M; Horak I; Conolly M; Ding C; Ouyang P; Kelly WK; Scher HI
J Clin Oncol; 1999 Mar; 17(3):948-57. PubMed ID: 10071289
[TBL] [Abstract][Full Text] [Related]
33. Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.
Mota JM; Armstrong AJ; Larson SM; Fox JJ; Morris MJ
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):522-530. PubMed ID: 31036925
[TBL] [Abstract][Full Text] [Related]
34. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL
Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815
[TBL] [Abstract][Full Text] [Related]
35. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.
Saylor PJ; Mahmood U; Kunawudhi A; Smith MR; Palmer EL; Michaelson MD
J Nucl Med; 2012 Nov; 53(11):1670-5. PubMed ID: 22984218
[TBL] [Abstract][Full Text] [Related]
36. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
Romero-Laorden N; Lorente D; de Velasco G; Lozano R; Herrera B; Puente J; López PP; Medina A; Almagro E; Gonzalez-Billalabeitia E; Villla-Guzman JC; González-Del-Alba A; Borrega P; Laínez N; Fernández-Freire A; Hernández A; Rodriguez-Vida A; Chirivella I; Fernandez-Parra E; López-Campos F; Isabel Pacheco M; Morales-Barrera R; Fernández O; Villatoro R; Luque R; Hernando S; Castellano DC; Castro E; Olmos D
Eur Urol Oncol; 2024 Jun; 7(3):447-455. PubMed ID: 37838555
[TBL] [Abstract][Full Text] [Related]
37. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
38. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
[TBL] [Abstract][Full Text] [Related]
39. Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors.
Fuerea A; Baciarello G; Patrikidou A; Albigès L; Massard C; Di Palma M; Escudier B; Fizazi K; Loriot Y
Eur J Cancer; 2016 Jul; 61():44-51. PubMed ID: 27151554
[TBL] [Abstract][Full Text] [Related]
40. Prognostic biomarkers in the use of radium-223 in patients with metastatic castration-resistent prostate cancer.
Vidal M; Cárdenas-Perilla R; Delgado A; Morón S; Londoño Blair JL; Vega I; Correa Ochoa JJ; Rojas J
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(5):310-318. PubMed ID: 37419250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
